DURHAM, N.C.–(BUSINESS WIRE)– #EHR–Sightview, the only EHR and practice management partner focused solely on eyecare, has appointed Melissa Wright and Casi Nestleroad as VPs.
Category: News
EyeDura's Sustained-Release Eye Drop Technology Wins Double Industry Honors
NEW YORK–(BUSINESS WIRE)–EyeDura Therapeutics Inc. (www.eyedura.com), a developer of preservative-free sustained release ophthalmic therapies, announced that it received top recognition at two major industry forums among a field of innovative ophthal…
Early Vitrectomy May Protect Vision in Post-Op Infections
Regardless of initial visual acuity, early vitrectomy can benefit patients who develop endophthalmitis after cataract surgery or intravitreal injection, a recent retrospective study shows. Medscape Medical News
Golden Age Health e Innostellar Biotherapeutics siglano un accordo di collaborazione esclusiva decennale per accelerare lo sviluppo della terapia genica LX-101 contro le distrofie retiniche ereditarie causate da mutazione del gene RPE65 in Cina
SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (“GAH”) e Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) oggi hanno annunciato la sigla di un accordo esclusivo decennale riguardante servizi di promozione che concede a GAH i diritti esclus…
Golden Age Health e Innostellar Biotherapeutics assinam colaboração exclusiva de 10 anos para acelerar a terapia gênica LX-101 voltada a distrofias hereditárias de retina causadas por mutação no gene RPE 65 na China continental
XANGAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (“GAH”) e a Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) anunciaram hoje um Contrato de Serviços Promocionais exclusivo por dez anos que concede à GAH direitos exclusivos para comercializar …
Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China
SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (“GAH”) and Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) today announced an exclusive ten-year Promotion Services Agreement that grants GAH sole rights to commercialise and promote Innoste…
Lock In Instant Definition and Volume with COVERGIRL’s NEW Mascara
NEW YORK–(BUSINESS WIRE)–Get ready to lock in lashes that feel stronger and protected with COVERGIRL’s latest addition to the Lash Blast portfolio. Say hello to NEW Lash Blast Bond Mascara, formulated to deliver instant definition and up to 5x visibl…
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release secon…
Samenvatting: Doorbraak in de oogheelkunde! Heng Qin® (perfluorohexyloctaan oogdruppels) van Hengrui goedgekeurd als eerste behandeling voor droge ogen geassocieerd met MGD
JIANGSU, China & HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co., Ltd. (‘Hengrui Pharma’), een wereldwijd farmaceutisch bedrijf gericht op wetenschappelijke en technologische innovatie, en Novaliq GmbH (‘Nov…
Riassunto: Novità nell'oftalmologia! Heng Qin®, il collirio al perfluorohexyloctane realizzato da Hengrui è stato approvato come primo trattamento per la sindrome dell'occhio secco associata alla MGD
JIANGSU, Cina, HEIDELBERG, Germania e CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), azienda farmaceutica globale incentrata sull’innovazione scientifica e tecnologica, e Novaliq GmbH (“Novaliq”), un’az…
Resumen: Gran avance en oftalmología: Heng Qin® de Hengrui (colirio de perfluorohexiloctano) aprobado como primer tratamiento para la sequedad ocular asociada a la Disfunción de las glándulas de Meibomio
JIANGSU, China y HEIDELBERG, Alemania y CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co. Ltd. («Hengrui Pharma»), una compañía farmacéutica internacional centrada en la innovación científica y tecnológica, y Novaliq GmbH (…
Study Finds Wide Pay Gaps in Eye Care
Inconsistent fees paid to doctors and facilities show the disadvantage independent clinicians face in the market. Medscape Medical News
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
GENEVA–(BUSINESS WIRE)–Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the C…
Efficacy and Toxicity Seen With MIRV in Ovarian Cancer
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer. Medscape Medical News
America’s Favorite Sports Pose a Risk for Orbital Fractures
Sports such as baseball, softball, and bicycling are the leading causes of orbital fractures in the US, particularly among adolescents and men, a retrospective cohort study shows. Medscape Medical News
Novartis Drug Cosentyx Fails Late-stage Trial for Artery Disease
Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the… Reuters Health Information
Despite Majority of Americans Struggling with the Impact of Poor Eyesight and Eye Health on Daily Life, More than Half Are Delaying or Avoiding Eye Care
NEW YORK–(BUSINESS WIRE)– #EyeCare–New Versant Health study finds 86% of Americans would seek eye exams if linked to overall health. Education, access and tech drive vision benefit use.
Eye Surgeon Raises Red Flag on Popular Lash Trend
Eyelash extensions are applied near the delicate ocular surface and may lead to serious complications like dry eye, keratitis, and lash misdirection. Medscape
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The…